Status:
COMPLETED
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Endo Pharmaceuticals
Collaborating Sponsors:
Alkermes, Inc.
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-80 years
Phase:
PHASE1
PHASE2
Brief Summary
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
Eligibility Criteria
Inclusion
- Male or female COPD patients between the ages of 40 and 80 years
- Smoking history of at least 10 pack years
- Not currently using (or able to wash out of) any long acting bronchodilators
Exclusion
- Candidate on a waiting list for surgery while on study
- Using long-term oxygen therapy
- Hospitalization for COPD exacerbation
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00465959
Start Date
April 1 2007
End Date
June 1 2007
Last Update
December 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
United States Investigational Site
Spartanburg, South Carolina, United States